

# Surgery of the Primary Tumour in Stage IV Colorectal Cancer with Unresectable Metastases

*Ninos Ayez*

*Wijnand J. Alberda*

*Henk M. Verheul*

*Jacobus W. Burger*

*Johannes H. de Wilt*

*Cornelis Verhoef*

*European Oncology & Haematology, 2011;8(1):27-31*

## Abstract

Since patients with incurable metastatic colorectal cancer (CRC) only have a relatively limited life expectancy, and resection of the primary tumour is accompanied by both morbidity and mortality, it is under debate whether resection of the primary tumour has an effect on survival or quality of life. The rationale behind the resection strategy is that prophylactic surgery prevents future complications. With current new chemotherapy regimens, a relatively low number of patients with metastatic CRC require surgery for their primary tumour. Many studies concerning the management of incurable stage IV CRC have been performed and most studies suggest a survival benefit for patients undergoing surgical resection of the primary tumour compared with those who received palliative treatment. However, in stage IV CRC with unresectable metastases, the role of a palliative resection of the primary tumour has never been assessed properly. Because randomised clinical trials are lacking, it is difficult to draw conclusions from the present literature.

## Introduction

Colorectal cancer (CRC) is one of the two most commonly diagnosed cancers, with approximately 1.2 million new cases each year and more than 600,000 annual deaths estimated to occur worldwide.<sup>1</sup> In addition, roughly one-fifth of patients presents with incurable disseminated disease.<sup>2</sup> In the last decade, development of new chemotherapeutic biological agents has significantly improved overall survival (OS) of these patients.<sup>3-12</sup>

A palliative resection of the primary tumor is frequently performed<sup>13</sup> and there is a clear indication for surgery when patients present with symptoms of the primary tumor. However, if patients present with absence or mild symptoms, the indication for resection is less obvious. Since patients with incurable metastatic CRC (mCRC) only have a relatively limited life expectancy and resection of the primary is accompanied with both morbidity and mortality<sup>14-16</sup>, it is under debate whether resection of the primary tumor has an effect on survival or quality of life.<sup>17,18</sup> Many studies concerning the management of incurable stage IV CRC have been performed; however the advantage of a palliative resection of the primary tumor has never been assessed properly.<sup>19</sup> Moreover, most studies do not even report whether a resection of the primary has been performed.<sup>20</sup>

In this paper we aim to evaluate the role of surgery of the primary in stage IV CRC with unresectable metastases.

## Treatment of metastatic colorectal cancer (mCRC)

At diagnosis of CRC, approximately 20% of the patients present with synchronous mCRC, and the liver is the predilection site in half these patients.<sup>21,22</sup> The lungs represent the second most common site of metastases from CRC and according to non population based studies lung metastases are present in 10-15% of patients with colorectal cancer.<sup>23,24</sup>

When metastases are limited, a possible curative treatment can be obtained by surgical resection, however, only 15-20% of patients is resectable.<sup>25</sup> Median 5-year survival for patients undergoing an R0 resection of the metastases is approximately 30% (range 15-67%).<sup>26</sup> Despite complete resection and neoadjuvant or adjuvant chemotherapy regimens, recurrences occur in 75% of the patients.<sup>27</sup> Extrahepatic disease in combination with liver metastases was generally considered a contraindication for surgery.<sup>28</sup> However, resection of both intrahepatic and extrahepatic colorectal metastases should be considered if resection of all metastatic sites can be complete and the disease is controlled by chemotherapy.<sup>29</sup>

In patients with unresectable metastases, palliative systemic chemotherapy is the treatment of choice. With systemic combination chemotherapy response rates of 40-70% have been reported resulting in a median overall survival rate of approximately

22 months.<sup>30-32</sup> Most frequently used combinations are oxaliplatin or irinotecan plus capecitabine or 5-fluorouracil (5-FU) with or without bevacizumab. In case of K-RAS wild type tumors, anti-epidermal growth factor receptor (EGFR) antibodies such as panitumumab and cetuximab are being used.<sup>33</sup>

## Resection of the primary tumor in patients with unresectable synchronous mCRC

Traditional surgical teaching promotes resection of the primary tumor in patients with unresectable metastases, even if the primary is asymptomatic. The rationale behind this strategy is that prophylactic surgery prevents future complications of intestinal obstruction, perforation and haemorrhage.<sup>34</sup> However, resection does not provide immediate palliative benefit in case of an asymptomatic primary tumor, and surgery is associated with high mortality (5-13%) and morbidity (23-48%) in patients with metastatic disease.<sup>34-37</sup> Some studies tried to selectively apply prophylactic surgery in patients with a low metastatic tumor burden because these patients are presumed to be at risk for obstruction because of long survival. If the metastatic tumor burden is extensive, resection of the primary is unlikely to benefit the patient and is associated with a high risk of postoperative complications. These patients are probably better served by focusing on the disseminated component of their disease and start with systemic treatment early on in their course, reserving surgery for when and if symptoms from the primary tumor are substantial.<sup>36,38</sup>

Other studies have shown no association between the incidence of complications and the extent of metastatic disease.<sup>39,40</sup> Due to recent advances in systemic chemotherapy, the risks and benefits of immediate or deferred surgical strategy are under debate.

Some clinicians in favor of the surgical approach argue that if the asymptomatic primary cancer is not resected, patients will develop disabling symptoms such as weight loss and nutritional depletion (secondary to "near" obstruction) and anemia due to bleeding of the primary tumor. Arguments supporting surgery include a lower reported operative mortality for elective surgery in patients with stage IV disease (3-6%), compared with the more threatening operative mortality rates for non-elective resections in patients with advanced and symptomatic disease (20-40%).<sup>34,41,42</sup> Another argument supporting this concept, is that preoperative staging is sometimes unclear and that surgery is considered the last and most effective diagnostic tool for the correct staging of abdominal tumors before treatment.<sup>19</sup> In addition, patients are provided with psychological comfort who feel that the "cancer" has been removed.<sup>36</sup>

## Chemotherapy first in patients with unresectable synchronous mCRC

The advocates of a chemotherapy first approach prefer to avoid complications at least in non symptomatic patients. The argument of those who prefer "elective" surgery due to higher mortality if emergent surgery is required, was addressed in several studies, where the risk of death was found to be extremely low.<sup>39,43-45</sup> In fact, Poultides et al. compared their study population with studies with elective colon resection in the metastatic setting and found that it appears that this deferred approach is associated with at least comparable perioperative mortality.<sup>46</sup> Another argument for chemotherapy first, is that chemotherapy will not only treat the metastases but also the primary tumor; many patients will have improvements of their symptoms and therefore evading a possible resection.<sup>35,47</sup> Chau et al. demonstrated that overall, 86% of patients had an improvement in symptoms. Of the patients with symptoms, 71% had diminished pelvic pain/ tenesmus, 90% had improvement in diarrhea/constipation, 100% had reduced rectal bleeding, and 93% had weight stabilization or weight gain.

Advocates of the deferred surgical approach argue that surgery at diagnosis can delay or even preclude systemic chemotherapy, and that most patients will never develop symptoms and these patients could be spared an unnecessary operation. Additionally, primary CRC surgery may alter the host immune response in such a way that tumor growth is increased in the post operative period.<sup>56,57</sup> An argument against resection is that patients with unresectable metastasis from colorectal cancer who have undergone palliative resection of the primary still face the prospect of further intestinal complications, which may require further surgery (*Table I*).<sup>34,48</sup> After resection of the primary tumor, these patients may develop local recurrence or adhesions which can result in obstruction and require subsequent surgery.

A decade ago, when patients were treated with single agent 5-FU chemotherapy, approximately 20% of patients with mCRC treated with chemotherapy required palliative surgery for symptoms related to their intact primary CRC.<sup>39,40,46,48,51</sup> In recent years, combinations with modern chemotherapy like FOLFOX, XELOX and FOLFIRI have attained response rates of 50% and disease control rates of 85% in prospective clinical trials.<sup>58</sup> With these *modern* chemotherapy regimens, approximately 7% (range 3-22%) of patients with mCRC required surgical palliation for their intact primary CRC, as stated in an elegant review by Poultides.<sup>43-46</sup> These data suggest that with effective chemotherapy almost 14 asymptomatic patients need to undergo prophylactic resection of their primary tumor in order to save one patient a subsequent operation for obstruction or perforation.<sup>46</sup> There are indications that this has led to a decrease over time in the percentage of resection of the primary tumor in case of unresectable metastatic colorectal disease.<sup>13</sup>

**Table I.** Study results on colorectal cancer and unresectable metastases, in which the non-resection arm was treated with chemotherapy

Author	Years of study		Number of patients	Received chemotherapy (%)	Secondary palliative surgical interventions	Palliative Resection of primary
Scoggins <sup>40</sup>	1985-1997	resection	66	0	2 (3%)	-
		chemo	23	100	2 (9%)	0
Tebbutt <sup>48</sup>	1990-1999	resection	280	100	14 (5%)	-
		chemo	82	100	8 (10%)	1 (1%)
Konyalian <sup>49</sup>	1991-2002	resection	62	58	#	-
		chemo	47	60	17 (36%)	0
Galizia <sup>50</sup>	1995-2005	resection	42	100	0	
		chemo	23	100	6 (26%)	¶
Ruo <sup>51</sup>	1996-1999	resection	127	0	6 (5%)	
		chemo	103	83	30 (29%)	0
Michel <sup>44</sup>	1996-1999	resection	31	97	0	
		chemo	23	100	5 (22%)	3 (13%)
Serela <sup>39</sup>	1997-2000	resection	-	-	-	
		chemo	24	88	6 (25%)	4 (17%)
Benoist <sup>43</sup>	1997-2002	resection	32	94	0	
		chemo	27	100	4 (15%)	3 (11%)
Karoui <sup>52</sup>	1998-2007	resection	85	99	27 (32%)	
		chemo	123	100	15 (12%)	15 (12%)
Aslam <sup>53</sup>	1998-2007	resection	366	63	¥	
		chemo	281	36	128 (46%)	0
Bajwa <sup>54</sup>	1999-2005	resection	-	-	-	
		chemo	67	100	27 (40%)	25 (37%)
Muratore <sup>45</sup>	2000-2004	resection	-	-	-	
		chemo	35	100	1 (3%)	0
Poultides <sup>35</sup>	2000-2006	resection	-	-	-	
		chemo	233	100	16 (7%)	8 (3%)
Seo <sup>55</sup>	2001-2008	resection	144	100	22 (15%)	
		chemo	83	100	4 (5%)	1 (1%)

# Konyalian<sup>53</sup> not described; 12 patients with complications mostly infectious; ¶ Galizia<sup>54</sup> not described; 2 colon perforations, 1 intestinal hemorrhage, 1 bowel obstruction, 2 surgery owing to bowel perforation or stent dislocation ¥ Aslam<sup>56</sup> not described; 11 full thickness wound dehiscence, 11 intra-abdominal collections, 11 anastomotic leak, 7 intra-abdominal sepsis, 5 hemorrhage, 4 postoperative ileus, 1 splenic tear, 1 inter-loop fistula

## Survival

Several studies have been performed to analyze overall survival of patients with stage IV CRC and unresectable metastases to examine whether to resect the primary or not. Recently, Venderbosch et al. performed a retrospective analysis of two phase III studies (CAIRO and CAIRO2)<sup>7,59</sup> and investigated the prognostic and predictive value of resection

of the primary tumor in stage IV mCRC patients.<sup>60</sup> They demonstrated that resection of the primary tumor was a significantly important prognostic factor for survival in these patients. They also performed a review of the literature and identified 22 nonrandomized studies, most of which showed improved survival for mCRC patients who underwent resection of the primary tumor. These results were confirmed in a systemic review by Anwar et al.<sup>57</sup> An overview of these studies is presented in *table 2*.

However, in all studies presented a selection bias cannot be excluded. Most studies were not randomized, performed in single centers and were retrospective of nature. Patients with a good performance status were more likely to undergo surgery whereas those with extensive disease were more likely to be offered chemotherapy instead. In the absence of randomized controlled trials, the best evidence is obtained from case-matched studies. A case-matched study by Benoist et al. compared 27 patients with asymptomatic colorectal cancer and irresectable synchronous liver metastases who received chemotherapy, with 32 matched patients who were treated by initial resection of the primary tumor. They found no difference in survival between the operative and the non-operative management.

Prospective studies on this topic are currently planned. Recently a protocol has been developed in the Netherlands for stage IV colon cancer patients with unresectable metastases.<sup>61</sup> In this trial patients will be randomized to either systemic therapy until progression or unacceptable toxicity or to resection of the primary tumor followed by systemic therapy until progression or unacceptable toxicity. The endpoint of the trial is overall survival and the trial is powered to identify a survival benefit of 6 months in the surgery group. Also the National Surgical Adjuvant breast and Bowel Project has started a phase II Trial using 5-fluorouracil, leucovorin, and oxaliplatin chemotherapy plus bevacizumab for patients with unresectable stage IV colon cancer and synchronous asymptomatic primary tumor.<sup>62</sup> The primary endpoint is the event rate related to the intact primary tumor requiring surgery. In both trials only patients with colon cancer will be randomized and patients with rectal cancer are excluded. Also a trial from Australia/New Zealand "SUPER" is currently running: "A randomized phase III multicentre trial evaluating the role of palliative surgical resection of the primary tumor in patients with metastatic colorectal cancer".<sup>63</sup> Patients will be randomized to compare chemotherapy followed by surgery to surgery alone. The primary outcome is to determine whether surgical resection of the primary tumor in patients with stage IV colorectal cancer decreases intestinal complications and improves overall survival and quality of life. For patients with rectal cancer and unresectable systemic disease a phase III randomized clinical trial is recently conducted in the Netherlands. In this trial the role of radiotherapy in providing local control will be studied and patients will be randomized to either standard chemotherapy alone or short term course radiotherapy (5x5 Gy) on the primary tumor followed by standard of care chemotherapy. The primary endpoint is the number of patients requiring an unplanned surgical intervention related to symptoms of the primary rectal tumor.

**Table II:** Studies Comparing Resection versus Non-resection of the Primary Tumour in Stage IV Colorectal Cancer and Unresectable Metastases

Author	Years of study		Number of patients	OS (months)	p value	Postoperative Mortality %	p-value
Makela <sup>34</sup>	1974-1983	Resection	66	15	—	5	—
		non-resection	30	7		17	
Scoggins <sup>40</sup>	1985-1997	Resection	66	14.5	0.59	5	—
		non-resection	23	16.6		—	
Liu <sup>16</sup>	1986-1991	Resection	57	11	—	9	—
		non-resection	6	3		17	
Tebbutt <sup>48</sup>	1990-1999	Resection	280	14	0.08	—	—
		non-resection	82	8.2		—	
Konyalian <sup>49</sup>	1991-2002	Resection	62	13	<0.0001	5	—
		non-resection	47	5		6	
Beham <sup>64</sup>	1993-2003	Resection	46	18	<0.001	3	—
		non-resection	21	8		0	
Costi <sup>19</sup>	1994-2003	Resection	83	9	<0.001	8	0.397
		non-resection	47	4		15	
Yun <sup>65</sup>	1994-2004	Resection	283	15.3	<0.001	3	—
		non-resection	93	5.3		—	
Stelzner <sup>66</sup>	1995-2001	Resection	128	11.4	<0.0001	12	0.784
		non-resection	58	4.6		10	
Galizia <sup>50</sup>	1995-2005	Resection	42	15.2	0.03	—	—
		non-resection	23	12.3		—	
Law <sup>15</sup>	1996-1999	Resection	150	7	<0.001	7	0.01
		non-resection	30	3		21	
Ruo <sup>51</sup>	1996-1999	Resection	127	16	<0.001	2	—
		non-resection	103	9		—	
Michel <sup>44</sup>	1996-1999	Resection	31	21	0.718	0	—
		non-resection	23	14		—	
Mik <sup>67</sup>	1996-2000	Resection	52	21	NS	—	—
		non-resection	82	14		—	
Benoist <sup>43</sup>	1997-2002	Resection	32	23	—	0	—
		non-resection	27	22		—	
Kaufman <sup>68</sup>	1998-2003	Resection	115	22	<0.0001	—	—
		non-resection	69	3		—	
Aslam <sup>53</sup>	1998-2007	Resection	366	14.5	<0.005	8	—
		non-resection	281	5.83		—	
Bajwa <sup>54</sup>	1999-2005	Resection	32	14	0.005	3	—
		non-resection	35	6		—	
Evans <sup>69</sup>	1999-2006	Resection	45	11	0.2056	16	—
		non-resection	57	7		36	

**Table II:** Studies Comparing Resection versus Non-resection of the Primary Tumour in Stage IV Colorectal Cancer and Unresectable Metastases (continued)

Author	Years of study		Number of patients	OS (months)	p value	Postoperative Mortality %	p-value
Chan <sup>70</sup>	2000-2002	Resection	286	14	<0.001	—	—
		non-resection	125	6		—	—
Frago <sup>71</sup>	2000-2008	Resection	12	39.1	0.008	8	—
		non-resection	43	1.0		6	—
Seo <sup>55</sup>	2001-2008	Resection	144	22	0.076	0	—
		non-resection	83	14		—	—
Venderbosch <sup>60</sup>	2003-2004	Resection	258	17	0.0001	—	—
		Non-resection	141	11		—	—
	2005-2006	Resection	289	21	0.0001	—	—
		Non-resection	159	13		—	—

*Resection was defined as resection of the primary tumour and non-resection was defined as surgical intervention without resection of the primary tumour. NS = not stated.*

## Summary

In stage IV CRC with unresectable metastases, the role of resection of the primary tumor remains unclear. Because randomized clinical trials are lacking, it is difficult to draw conclusions from the present literature. With current new chemotherapy regimen, including VEGF and EGF inhibitors, a relatively low number of patients with mCRC require surgery for their primary tumor. Most studies suggest a survival benefit for patients undergoing surgical resection of the primary tumor compared to those who received palliative treatment. However, these results are likely to be influenced by selection bias and therefore prospective randomized controlled trials are needed to address this question.

## References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**(2): 69-90.
2. Mella J, Biffin A, Radcliffe AG, Stamatakis JD, Steele RJ. Population-based audit of colorectal cancer management in two UK health regions. Colorectal Cancer Working Group, Royal College of Surgeons of England Clinical Epidemiology and Audit Unit. *Br J Surg* 1997; **84**(12): 1731-6.
3. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol* 2000; **18**(16): 2938-47.
4. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet* 2000; **355**(9209): 1041-7.
5. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol* 2010; **28**(31): 4697-705.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004; **350**(23): 2335-42.
7. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. *Lancet* 2007; **370**(9582): 135-42.
8. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol* 2008; **26**(12): 2013-9.
9. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. *N Engl J Med* 2000; **343**(13): 905-14.
10. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. *Lancet* 2007; **370**(9582): 143-52.
11. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol* 2004; **22**(2): 229-37.
12. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009; **360**(14): 1408-17.
13. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. *Ann Surg Oncol* 2005; **12**(8): 637-45.
14. Harris GJ, Senagore AJ, Lavery IC, Church JM, Fazio VW. Factors affecting survival after palliative resection of colorectal carcinoma. *Colorectal Dis* 2002; **4**(1): 31-5.
15. Law WL, Chan WF, Lee YM, Chu KW. Non-curative surgery for colorectal cancer: critical appraisal of outcomes. *Int J Colorectal Dis* 2004; **19**(3): 197-202.
16. Liu SK, Church JM, Lavery IC, Fazio VW. Operation in patients with incurable colon cancer— is it worthwhile? *Dis Colon Rectum* 1997; **40**(1): 11-4.

17. Joffe J, Gordon PH. Palliative resection for colorectal carcinoma. *Dis Colon Rectum* 1981; **24**(5): 355-60.
18. Stearns MW, Jr, Binkley GE. Palliative surgery for cancer of the rectum and colon. *Cancer* 1954; **7**(5): 1016-9.
19. Costi R, Mazzeo A, Di Mauro D, et al. Palliative resection of colorectal cancer: does it prolong survival? *Ann Surg Oncol* 2007; **14**(9): 2567-76.
20. Sorbye H, Kohne CH, Sargent DJ, Glimelius B. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. *Ann Oncol* 2007; **18**(10): 1666-72.
21. Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. *Cancer* 1969; **23**(1): 198-202.
22. van der Pool AE, Lalmahomed ZS, Ozbay Y, et al. 'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome. *Colorectal Dis* 2010; **12**(10 Online): e229-35.
23. Choi DJ, Kwak JM, Kim J, Woo SU, Kim SH. Preoperative chest computerized tomography in patients with locally advanced mid or lower rectal cancer: its role in staging and impact on treatment strategy. *J Surg Oncol* 2010; **102**(6): 588-92.
24. Tan KK, Lopes Gde L, Jr, Sim R. How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years. *J Gastrointest Surg* 2009; **13**(4): 642-8.
25. Adam R, Hoti E, Bretd LC. Evolution of neoadjuvant therapy for extended hepatic metastases—have we reached our (non-resectable) limit? *J Surg Oncol* 2010; **102**(8): 922-31.
26. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. *Br J Cancer* 2006; **94**(7): 982-99.
27. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet* 2008; **371**(9617): 1007-16.
28. Hugh TJ, Kinsella AR, Poston GJ. Management strategies for colorectal liver metastases—Part II. *Surg Oncol* 1997; **6**(1): 31-48.
29. Adam R, de Haas RJ, Wicherts DA, et al. Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery? *Ann Surg* 2011; **253**(2): 349-59.
30. Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. *BMC Cancer* 2007; **7**: 91.
31. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. *Ann Oncol* 2009; **20**(11): 1842-7.
32. Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. *Cancer Chemother Pharmacol* 2008; **62**(2): 195-201.
33. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; **26**(10): 1626-34.

34. Makela J, Haukipuro K, Laitinen S, Kairaluoma MI. Palliative operations for colorectal cancer. *Dis Colon Rectum* 1990; **33**(10): 846-50.
35. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. *J Clin Oncol* 2009; **27**(20): 3379-84.
36. Rosen SA, Buell JF, Yoshida A, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? *Arch Surg* 2000; **135**(5): 530-4; discussion 4-5.
37. Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. *World J Surg* 2010; **34**(4): 797-807.
38. Stillwell AP, Buettner PG, Siu SK, Stitz RW, Stevenson AR, Ho YH. Predictors of postoperative mortality, morbidity, and long-term survival after palliative resection in patients with colorectal cancer. *Dis Colon Rectum* 2011; **54**(5): 535-44.
39. Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O'Riordain DS. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. *Br J Surg* 2001; **88**(10): 1352-6.
40. Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. *Ann Surg Oncol* 1999; **6**(7): 651-7.
41. Legendre H, Vanhuysse F, Caroli-Bosc FX, Pector JC. Survival and quality of life after palliative surgery for neoplastic gastrointestinal obstruction. *Eur J Surg Oncol* 2001; **27**(4): 364-7.
42. Longo WE, Virgo KS, Johnson FE, et al. Risk factors for morbidity and mortality after colectomy for colon cancer. *Dis Colon Rectum* 2000; **43**(1): 83-91.
43. Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. *Br J Surg* 2005; **92**(9): 1155-60.
44. Michel P, Roque I, Di Fiore F, et al. Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? *Gastroenterol Clin Biol* 2004; **28**(5): 434-7.
45. Muratore A, Zorzi D, Bouzari H, et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? *Ann Surg Oncol* 2007; **14**(2): 766-70.
46. Poultsides GA, Paty PB. Reassessing the need for primary tumor surgery in unresectable metastatic colorectal cancer: overview and perspective. *Ther Adv Med Oncol* 2011; **3**(1): 35-42.
47. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. *J Clin Oncol* 2006; **24**(4): 668-74.
48. Tebbutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. *Gut* 2003; **52**(4): 568-73.
49. Konyalian VR, Rosing DK, Haukoos JS, et al. The role of primary tumour resection in patients with stage IV colorectal cancer. *Colorectal Dis* 2007; **9**(5): 430-7.

50. Galizia G, Lieto E, Orditura M, et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. *Arch Surg* 2008; **143**(4): 352-8; discussion 8.
51. Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. *J Am Coll Surg* 2003; **196**(5): 722-8.
52. Karoui M, Roudot-Thoraval F, Mesli F, et al. Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. *Dis Colon Rectum* 2011; **54**(8): 930-8.
53. Aslam MI, Kelkar A, Sharpe D, Jameson JS. Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers. *Int J Surg* 2010; **8**(4): 305-13.
54. Bajwa A, Blunt N, Vyas S, et al. Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. *Eur J Surg Oncol* 2009; **35**(2): 164-7.
55. Seo GJ, Park JW, Yoo SB, et al. Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer. *J Surg Oncol* 2010; **102**(1): 94-9.
56. Allendorf JD, Bessler M, Horvath KD, Marvin MR, Laird DA, Whelan RL. Increased tumor establishment and growth after open vs laparoscopic surgery in mice may be related to differences in postoperative T-cell function. *Surg Endosc* 1999; **13**(3): 233-5.
57. Anwar S, Peter MB, Dent J, Scott NA. Palliative excisional surgery for primary colorectal cancer in patients with incurable metastatic disease. Is there a survival benefit? A systematic review. *Colorectal Dis* 2012; **14**(8): 920-30.
58. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2004; **22**(1): 23-30.
59. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med* 2009; **360**(6): 563-72.
60. Venderbosch S, de Wilt JH, Teerenstra S, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. *Ann Surg Oncol* 2011; **18**(12): 3252-60.
61. <http://www.dccg.nl/>. TDCCGAa.
62. National Surgical Adjuvant Breast and Bowel Project [Protocol C-10 APITo-F, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy Plus Bevacizumab for Patients with Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor. web site]. Available at: [http://www.nsabppittedu/C10\\_Information.asp](http://www.nsabppittedu/C10_Information.asp)
63. colorectal cancer. web site]. ANZCTRTRSSArpImtetrosprotptipwm. Available at: [http://www.anzctrorgau/trial\\_view.aspx?ID=308218\\_147](http://www.anzctrorgau/trial_view.aspx?ID=308218_147)
64. Beham A, Rentsch M, Pullmann K, et al. Survival benefit in patients after palliative resection vs non-resection colon cancer surgery. *World J Gastroenterol* 2006; **12**(41): 6634-8.
65. Yun HR, Lee WY, Lee WS, Cho YB, Yun SH, Chun HK. The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient's status. *Int J Colorectal Dis* 2007; **22**(11): 1301-10.
66. Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. *J Surg Oncol* 2005; **89**(4): 211-7.

67. Mik M, Dziki L, Galbfach P, Trzcinski R, Sygut A, Dziki A. Resection of the primary tumour or other palliative procedures in incurable stage IV colorectal cancer patients? *Colorectal Dis* 2010; **12**(7 Online): e61-7.
68. Kaufman MS, Radhakrishnan N, Roy R, et al. Influence of palliative surgical resection on overall survival in patients with advanced colorectal cancer: a retrospective single institutional study. *Colorectal Dis* 2008; **10**(5): 498-502.
69. Evans MD, Escofet X, Karandikar SS, Stamatakis JD. Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer. *World J Surg Oncol* 2009; **7**: 28.
70. Chan TW, Brown C, Ho CC, Gill S. Primary tumor resection in patients presenting with metastatic colorectal cancer: analysis of a provincial population-based cohort. *Am J Clin Oncol* 2010; **33**(1): 52-5.
71. Frago R, Kreisler E, Biondo S, Salazar R, Dominguez J, Escalante E. Outcomes in the management of obstructive unresectable stage IV colorectal cancer. *Eur J Surg Oncol* 2010; **36**(12): 1187-94.